Biogen MS drug Plegridy OK'd; can it compete?
This article was originally published in Scrip
Executive Summary
The wait is over for Biogen Idec on its latest multiple sclerosis drug Plegridy (peginterferon beta-1a), with the Cambridge, Massachusetts company receiving word late on 15 August the FDA approved the medicine as a treatment for relapsing forms of the disease – the first and only pegylated beta interferon OK'd for the condition in the US.